Pooling three cohorts, patients who took an SGLT2 inhibitor during or after acute kidney injury had 35% lower all-cause mortality (adjusted HR 0.65, 95% CI 0.59-0.71). Major adverse kidney events were also lower (OR 0.63, 95% CI 0.44-0.88), though that estimate was highly heterogeneous (I2 = 91%) and collapsed when single studies were excluded. The sole randomized trial, with 200 patients, could not confirm benefit for mortality or kidney events. GRADE certainty was very low.
The mortality signal looks impressive, but it comes almost entirely from observational data, and the likeliest explanation is confounding by indication. Clinicians prescribe SGLT2 inhibitors to patients who are stable, eating, and expected to survive, while frail or septic patients are passed over, so drug users would look healthier even if the drug did nothing. A hazard ratio this large after AKI is more plausible as selection than as pharmacology. The mechanistic case is sound, since these drugs reduce intraglomerular pressure and slow chronic kidney disease progression, and AKI is a major driver of later CKD. Still, plausibility is not proof. This analysis is confirmatory of an open question rather than a paradigm shift. For adults with diabetes, heart failure, or CKD who have survived AKI, the practical point is to ask the treating nephrologist whether and when to restart or start an SGLT2 inhibitor, since existing trials already support these drugs for those underlying conditions. Dedicated randomized trials in AKI survivors are needed before anyone should treat this as a standalone indication.